Factors associated with macrosomia, hypoglycaemia and low Apgar score among Fijian women with gestational diabetes mellitus by Fuka, Falahola et al.
RESEARCH ARTICLE Open Access
Factors associated with macrosomia,
hypoglycaemia and low Apgar score
among Fijian women with gestational
diabetes mellitus
Falahola Fuka1†, Uchechukwu L. Osuagwu2* , Kingsley Agho3,4, Rajat Gyaneshwar5†, Swaran Naidu5†,
James Fong6† and David Simmons2
Abstract
Background: Gestational diabetes mellitus (GDM) in Fiji is a serious public health issue. However, there are no
recent studies on GDM among pregnant women in Fiji. The aim of this study was to examine prevalence of, and
sociodemographic factors associated with adverse neonatal outcomes among Fijian women with GDM.
Methods: We used cross-sectional data of 255 pregnant women with GDM who gave birth to singleton infants at
Colonial War Memorial Hospital (CWMH) in Suva city. Women underwent testing for GDM during antenatal clinic visits
and were diagnosed using modified International Association of Diabetes and Pregnancy Study Groups (IADPSG)
criteria. Multivariable logistic regression analysis was used to investigate factors associated with neonatal outcomes.
Results: Women with a previous baby weighing > 4 kg were 6.08 times more likely to experience neonatal
macrosomia (Adjusted odds ratio (AOR) = 6.08; 95%CI: 2.46, 15.01). Compared to unmarried women, the odds of
macrosomia among married women reduced by 71% (AOR = 0.29; 95%CI: 0.11, 0.77). Compared with delivery before
38 weeks of gestation, the infants of women who delivered between 38 and 41 weeks of gestation were 62 and 86%
less likely to experience neonatal hypoglycaemia and Apgar score < 7 at 5 mins, respectively. The offspring of women
who were overweight and obese had higher odds of neonatal hypoglycaemia. Late booking in gestation (≥28 weeks)
was significantly associated with Apgar score < 7 at 5 min (AOR = 7.87; 95%CI: 1.11, 55.75). Maternal pre-eclampsia/
pregnancy induced hypertension was another factor associated with low Apgar score in infants.
Conclusions: The study found high rates of adverse neonatal outcomes among off springs of Fijian women with GDM
and showed that interventions targeting pregnant women who are overweight, had a previous baby weighing > 4 kg,
had pre-eclampsia, delivered before 38 weeks of gestation, and those who booked later than 13 weeks in gestation, are
needed to improve pregnancy outcomes.
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Introduction
Gestational diabetes mellitus (GDM) is any degree of
glucose intolerance that occurs or is diagnosed for the
first time during pregnancy [1]. Women with GDM are
at high risk of pregnancy complications, including infant
macrosomia, neonatal hypoglycaemia, low Apgar score
and caesarean delivery [2], have more than a 7-fold in-
creased risk of developing type 2 diabetes 5 to 10 years
after delivery [3], and the risk is even higher in obese
women with GDM [4]. Children born to mothers with
GDM are more likely to develop impaired glucose toler-
ance later in life, [5] and early detection and appropriate
therapy may prevent these complications [6, 7].
Globally, it is estimated that GDM affects between 1
and 36% of pregnancies, depending on the population
studied and the diagnostic tests used [2]. Among Pacific
people, previous studies conducted in 2008 reported that
about 20% of pregnancies are complicated by GDM [8]
but lower rates have been documented among European
women living in Auckland who delivered between 1994
and 1995 [9], and White-skinned women in Hawaii, who
delivered between 2010 and 2011 [10], compared with
Pacific Island women. Lower rates of GDM were re-
ported among Pacific Islands women living in Australia
(6.3%) [11] and in the US (8.3%) [12], between 2010 and
2011 using the Australasian Diabetes in Pregnancy Soci-
ety (ADIPS) [1] and the American Diabetes Association
(ADA) diagnostic criteria [12]. Independent of maternal
body weight, age, parity and education, women particu-
larly those from Pacific countries who were born in their
home countries were more likely to have GDM than
their counterparts who were born in foreign countries
[12]. The authors suggested that the varying degrees of
access to medical care, especially recent immigrants who
may be less likely to undergo screening for GDM,
coupled with other environmental factors in migrant
populations may interact with genetic susceptibility to
influence the risk of GDM [12].
Fiji has high and increasing rates of obesity and type 2
diabetes among non-pregnant individuals [13] suggesting
a high prevalence of gestational diabetes mellitus (GDM),
and associated adverse pregnancy outcomes. Maternal
obesity and type 2 diabetes were additive for increased risk
of GDM [14]. However, there is no up-to-date evidence
on the prevalence of, and outcomes from, pregnancies
complicated by GDM in Fiji, and a meta-analysis failed to
find reliable data on GDM in Pacific Island countries [15].
Prior epidemiological studies from Fiji were either con-
ducted more than three decades ago (1983 [16] and 1990)
[17], and/or used diagnostic criteria for GDM (O’Sullivan
and Mahan 1964 [17] and WHO 1980 [16]) that are no
longer in use. Gyaneshwar and Ram [17] found a higher
prevalence of GDM among Fijians of Indian Descent
(FIDs) compared with ITaukei Fijians (5% vs 0.6%) and
the rate was higher among women who had higher BMI
[17]. Zimmet et al. [16] found rural-urban differences in
prevalence of diabetes in a Melanesian population with
greater differences among women, but no difference was
found between rural-urban dwellers among the Indian
population. Since these studies (1989–2018), the rates of
obesity and diabetes among Pacific Island countries [18]
including Fiji [13] have more than doubled, and the cri-
teria for GDM diagnosis in the previous studies were not
designed to identify women at risk of adverse perinatal
outcomes but to identify those at high risk of subsequently
developing type 2 diabetes [19].
In the Colonial War Memorial Hospital (CWMH) Fiji,
GDM was previously diagnosed using the ADIPS criteria
which consisted of a 75 g glucose load with a fasting blood
glucose ≥5.5mmol/l and 2 h ≥8.0mmol/l and only pregnant
women with known risk factors for GDM such as previous
GDM and previous big babies, were tested for GDM. In
2013, the hospital commenced a 2-step process of universal
testing for GDM, using the modified International Associ-
ation of Diabetes and Pregnancy Study Groups (IADPSG)
criteria described in Fig. 1. Adoption of these criteria
followed the findings of the landmark HAPO observational
study in 2008 which reported significant relationship be-
tween maternal glycaemic levels and pregnancy outcomes
[20]. Implementation of the modified (IADPSG) criteria was
expected to not only increase the prevalence of GDM, but
also to identify the population at higher risk of adverse preg-
nancy outcomes and who may benefit from targeted inter-
ventions to improve pregnancy outcomes [21].
Fijians are genetically different from other populations
[22] and along with other Pacific Island nations make up
eight of the world’s 10 most obese countries [23]. Pacific
Islander women are heavier during pregnancy, have
higher rates of macrosomia, higher incidence of abnor-
mal glucose tolerance test results post-partum [17], and
hence a higher risk of future development of type 2 dia-
betes mellitus compared to other ethnic groups [24].
This study was conducted to provide recent evidence
on the prevalence of, and socio-demographic factors as-
sociated with, adverse neonatal outcomes among women
with GDM in Fiji. The findings of this study are import-
ant to inform local policy and should enable public
health researchers to target a sub-population of women
with GDM for future interventions and allocation of
local resources to areas with high need. The study is also
likely to inform practice in rural/remote areas in Fiji and
those with significant Melanesian and Polynesian popu-
lations (e.g. New Zealand and Australia).
Subjects and methods
Setting
Fiji is an island nation in the south-west Pacific Ocean,
located between Vanuatu and Tonga. As at 2011, the
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country has a total population of approximately 884,887
(50.7% men, 49.3% women) which is comprised of about
57% Indigenous Fijians (iTaukei), 37% FIDs, and 6%
others (including other Pacific people, Chinese and those
of European descent). Indigenous Fijians are predomin-
antly of Melanesian extraction, with some Polynesian ad-
mixture. About 56% of Fiji’s population resides in urban
areas, with the Suva region being the most heavily popu-
lated [25]. Colonial War Memorial Hospital (CWMH) in
Suva is Fiji’s largest and oldest hospital, and the national
referral hospital for Fiji with services that are accessed
by other Pacific Island countries [26].
Data sources
Data for 255 women with GDM who gave birth to
singleton infants at CWMH in Suva between June 2013
and May 2014, were retrieved from the Diabetes in preg-
nancy registry; the timeframe 2013–2014 was chosen be-
cause it was when the modified IADPSG [27] criteria for
GDM diagnosis were introduced in the hospital. In our
analysis, women with pre-existing diabetes i.e. those with
known type 1 and type 2 diabetes, were excluded (Fig. 1).
Sample size
The required sample size for this study was determined
using a single population proportion formula. An earlier
study reported in 1983 that the prevalence of GDM in
Fiji was 22.7% [16]. This present study assumed the dif-
ferences in the prevalence of GDM between urban and
rural Fijians ranged between 5 and 7% [16], at 80%
power and 5% significance level. This gives a sample of
251 women with GDM. Taking into account a dropout
rate of about 2%, also based on earlier research [16], a
total sample of approximately 255 participants was re-
quired. This sample size was sufficient to detect any stat-
istical differences in examining factors associated with
GDM among Fijian women.
Fig. 1 Flow chart for gestational diabetes mellitus (GDM) testing among pregnant women in an urban Fiji hospital. All pregnant women are
routinely tested for GDM using a two-step process consisting of the 1-h glucose challenge test (GCT) at 24–28 weeks including a non-fasting 50 g
glucose load and if GCT was ≥ 7.8 mmol/l, a 2-h 75 g oral glucose tolerance test (OGTT) was then performed. One abnormal value is sufficient for
diagnosis. The women with any known risk factor for GDM including age≥ 30 years, strong family history of diabetes, past history of GDM,
previous macrosomic baby and high maternal pre-pregnancy BMI≥ 30 kg/m2, proceed to OGTT at initial testing. Those who are at high risk for
GDM (i.e. women with two or more of the risk factors present at booking) proceed directly to a 2-h 75 g OGTT at the time of their booking with
the antenatal clinic. If the early testing with OGTT was normal (fasting < 5.1 mmol/L, 2 h < 8.5 mmol/L), the high-risk women underwent another
75-g OGTT at 24–28 weeks’ gestation
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Outcome variables
To determine the outcome variables, we conducted pre-
liminary analysis using frequency distribution for all the
neonatal outcomes (see dotted vertical line in Fig. 2) and
only those with proportions > 10% were retained as final
outcome variables. This was done to avoid the loss in pre-
cision of estimates with wide confidence intervals [28].
The three neonatal outcome variables that were retained
in the analysis included: neonatal hypoglycaemia (which
was defined as neonatal glucose ≤1.6mmol/l during the
first 24 h after birth [29]), macrosomia (baby weighing> 4
kg) [20] and Apgar score < 7 after 5min. The outcome
variables were coded as binary, ‘1’ for the presence and ‘0’
for absence. In our analysis, we combined data for those
with GDM and DIP due to low count of women with DIP.
Potential cofounding factors
The choice of potential cofounding factors was based on
previous studies [30–32] and included socio-demographic
factors (age, ethnicity, marital status, parity, level of educa-
tion); maternal factors such as body mass index (BMI) cal-
culated at the first prenatal visit using WHO criteria as:
underweight (< 18.5 kg/m2), normal (18.5–24.9 kg/m2),
and overweight (from 25 to 29.9 kg/m2), class 1 obesity
(30–34.9 kg/m2) and class 2/3 obesity ≥35 kg/m2 [33],
positive family history of diabetes, past history of GDM,
baby weighing > 4 kg, stillbirth and neonatal death (which
were simply recorded as present or absent); antenatal
factors (gestational age at booking, gestational age at
diagnosis and gestational age at delivery); and maternal
complications such as preeclampsia (defined as hyperten-
sion that is onset from at least 20 weeks of pregnancy and
accompanied by proteinuria), polyhydramnios, trauma,
endometritis and wound infection and mode of delivery
(caesarean section and vaginal delivery). Gestational age at
delivery was classified into < 37 weeks and ≥ 37 weeks. In
the regression analysis, BMI was further collapsed into
three categories normal, overweight and obese due to low
count of underweight, class 2 and class 3 obese women,
and levels of education were classified into non-tertiary
(no education, primary, secondary) and tertiary (university
and polytechnic).
Statistical analysis
Analyses involved frequency tabulations of all con-
founding factors in the study population. This was
followed by cross tabulation to determine the preva-
lence of all potential confounding factors. Univariate
logistic regression and multivariable logistic regression
were performed to determine factors associated with
the three key neonatal outcomes of macrosomia, neo-
natal hypoglycaemia and low Apgar score among off-
spring of women with GDM. The odds ratios with
95% confidence intervals were calculated to assess the
adjusted odds of the independent variables. All ana-
lyses were carried out using STATA/MP version 14
(Stata Corp, College Station, TX, USA).
Fig. 2 Prevalence of neonatal outcomes among Fijian women with gestational diabetes mellitus (GDM). LGA, large for gestational age
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Ethics
The study used existing datasets that are available from
patients’ records, and all identifier information was re-
moved prior to analysis. The study was approved by the
Ethics Committee of the College of Medical Nursing
and Health Sciences of the Fiji National University and
by the Fiji National Health Research Ethics Review Com-
mittees (ref #: 2015.48.CEN).
Results
Characteristics of Fijian women with GDM
The majority were married (88.2%) women who were
aged between 26 and 35 years (62.8%) and about one-
third had tertiary education (37.2%). The sample had al-
most equal proportion of Itaukei Fijians and FIDs (49.4%
vs 42.0%), the two main ethnic groups in Fiji. Table 1
shows the characteristics of women with GDM in
CMWH Fiji. About one-half of mothers booked between
14 and 27 weeks of gestation. A hundred and seventy-
three women (67.8%) had vaginal delivery (majority were
non-assisted/normal vaginal deliveries (n = 165, 64.7%))
and 32.2% delivered by caesarean section. As indicated
in Fig. 2, about 24.7% of the women with GDM had
hypoglycaemic infants, 23.1% had macrosomic infants,
and 12.9% had infants with Apgar scores < 7 at 5 min.
Shoulder dystocia, stillbirth, premature delivery, large for
gestational age (LGA) babies and NICU admissions were
other serious adverse neonatal outcomes observed
among Fijian women with GDM with prevalence < 10%,
each.
Factors associated with macrosomia among Fijian women
with GDM
Table 2 shows the prevalence, univariate and multivari-
able regression analysis of factors associated with neo-
natal macrosomia. As indicated in the table, univariate
analysis indicated that race or ethnicity, marital status,
previous baby weighing > 4 kg, gestational age at book-
ing, gestational age at GDM diagnosis and gestational
age at delivery were significantly associated with neo-
natal macrosomia. After adjusting for potential con-
founding factors, our results revealed that marital status
(married) and having a previous baby weighing > 4 kg
were significantly associated with neonatal macrosomia.
Factors associated with neonatal hypoglycaemia among
Fijian women with GDM
The prevalence, univariate and multivariable regression
analysis of factors associated with neonatal hypoglycaemia
are presented in Table 3. From the table, it can be seen
from the univariate analysis that maternal BMI and gesta-
tional age at delivery were significantly associated with
neonatal hypoglycaemia. After adjusting for potential con-
founding factors, our results revealed that gestational age
at delivery (< 37 weeks of gestation) and maternal BMI
(overweight, BMI of 25–29.9 kg/m2) were significantly as-
sociated with neonatal hypoglycaemia.
Prevalence and factors associated with neonatal low
Apgar Score < 7 at 5min
Table 4 shows the prevalence, univariate and multivari-
able regression analysis of factors associated with neo-
natal Apgar score < 7 at 5 min. As indicated in the table,
univariate analysis indicated that gestational age at deliv-
ery was significantly associated with neonatal low Apgar
score. After adjusting for potential confounding factors,
our results revealed that gestational age at booking (≥28
weeks) and at delivery (< 37 weeks), and maternal pre-
eclampsia, were significantly associated with neonatal
low Apgar score among Fijian women with GDM.
Discussion
In the last 30 years, this is the first study to provide evi-
dence of GDM and associated outcomes among Fijian
women. We found high rates of adverse neonatal out-
comes in this population which far exceeded the rates
for the background population and in some cases almost
doubled the rate [34] and they were far above the rates
among other Pacific Islander women [32, 35, 36]. The
key factors associated with such high rates of neonatal
outcomes among Fijian women with GDM included pre-
vious baby weighing > 4 kg, maternal BMI (overweight/
obese), gestational age at booking (≥28 weeks) and gesta-
tional age at delivery (< 37 weeks), and maternal pre-
eclampsia or pregnancy-induced hypertension. Also of
importance in this population were obesity, ethnicity,
and a family history of diabetes, which interacted with
other variables to influence the odds of neonatal out-
comes in this study.
The proportion of women who had macrosomic babies
(23%) in this study (see Fig. 2) was comparable to the
global report in GDM (15–45%) but the rates almost
doubled the reported rate among other Pacific Islands
women with [32, 35–38] and without GDM (12%) [39].
This may be related to the high rate of obesity in this co-
hort (where 68% of the women were obese, Table 1) - a
reflection of the obesity epidemic in the country. The
finding of a significant association between macrosomia
and previous baby weighing > 4 kg was consistent with
previous reports from observational [40, 41] and cohort
studies [42] that showed a strong relationship between
macrosomia and a previous history of macrosomia. In
the observational study, the authors found that up to
78% of the women who reported a previous history of
macrosomia had repeat macrosomia [41]. It is known
that all macrosomic infants represent a high-risk group,
regardless of maternal diabetes status [43, 44]. Clausen
et al. in 2005 [45] and Schaefer-Graf in 2003 [46]
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reported similar data. They found that high HbA1c at ad-
mission and maternal BMI were independently associ-
ated with serious adverse fetal outcomes including
perinatal mortality and/or major congenital malforma-
tions [45], and maternal BMI and previous macrosomic
baby appear to have the strongest influence on fetal
growth in the late second and early third trimester; ma-
ternal glycaemia predominated in the third trimester
[46]. It was suggested that the process leading to macro-
somia in infants starts in the second trimester of preg-
nancy [47], however, other studies have found a
relationship of some factors in 1st trimester that corre-
lated with macrosomia [48, 49]. These findings suggest
the need for early identification of the women with
GDM (particularly those at high risk) for interventions
that could potentially reduce the rate of macrosomia
and other outcomes associated with macrosomia such as
shoulder dystocia and caesarean section deliveries which
were also higher in this study compared to the back-
ground population [50].
Table 1 Maternal Characteristics of Fijian women with GDM
Study characteristics n = 255 %
Maternal sociodemographic characteristics
Age (years) 30.7 ± 5.5
18–25 46 18.0
26–35 160 62.8
≥ 36 49 19.2
Race/ethnicity
Others§ 22 8.6
Itaukei Fijians 126 49.4
FIDs 107 42.0
Educational levelǂ
Non-tertiary (primary/secondary) 157 62.8
Tertiary (university/polytechnic) 93 37.2
Marital status
Not married 30 11.8
Married 225 88.2
Gravidity (number of pregnancies)
Primigravid (first pregnancy) 34 13.3
Multiparous (2/more children) 177 69.4
Grand multiparous (≥5 children) 44 17.3
Maternal risk factors (yes, no)
Family history of diabetes
Yes 128 50.2
No 127 49.8
Previous history of GDM
Yes 11 4.3
No 244 95.7
Previous baby > 4 kg
Yes 55 21.6
No 200 78.4
Previous stillbirth
Yes 11 4.3
No 244 95.7
Previous neonatal death
Yes 10 3.9
No 245 96.1
Maternal BMI (kg/m2)ǂ 33.2 ± 7.5
Underweight/normal (< 25) 35 14.9
Overweight (25–29.9) 40 17.0
Obese (classes 1–3, ≥30.0) 160 68.1
Antenatal factors (weeks)
Gestational age at booking 18.9 ± 7.5
1st trimester (0–13) 79 31.0
2nd trimester (14–27) 134 52.6
3rd trimester (≥28) 42 16.5
Table 1 Maternal Characteristics of Fijian women with GDM
(Continued)
Study characteristics n = 255 %
Gestational age at GDM diagnosis 25.6 ± 7.8
1st trimester (0–13) 26 10.2
2nd trimester (14–27) 111 43.5
3rd trimester (≥27) 118 46.3
Gestational age at delivery 38.3 ± 2.2
< 37 44 17.2
37–41 211 82.8
Maternal post-pregnancy factors
Mode of delivery
Vaginal delivery 173 67.8
Caesarean section 82 32.2
Induced labour
Yes 98 38.4
No 157 61.6
Preeclampsia
Yes 48 18.8
No 207 81.2
Polyhydramnios
Yes 2 0.8
No 253 99.2
Infectionǂ
Yes 3 1.2
No 251 98.8
BMI body mass index, GDM gestational diabetes mellitus, FIDs Fijians of
Indian Descent
§others means part-Europeans, Chinese, and other Pacific Islanders
ǂthere were few missing data, so the denominator was less than 255
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Table 2 Prevalence, unadjusted (OR) and odds ratios (AOR) for neonatal macrosomia among Fijian women with GDM, 2013–2014
Variables Prevalence of macrosomia (%) OR 95% CI AOR 95% CI
Maternal sociodemographic characteristic
Age (years)
18–25 17.4 1.00 1.00
26–35 25.0 1.58 0.68, 3.68 1.27 0.44, 3.72
≥ 36+ 22.5 1.38 0.50, 3.80 0.70 0.17, 2.89
Race/ethnicity
Others§ 31.8 1.00 1.00
Itaukei Fijians 31.0 0.96 0.95 0.29, 3.12
FIDs 12.2 0.30 0.10,0.80* 0.50 0.12, 2.02
Educational level
Non-tertiary (primary/secondary) 24.2 1.00 1.00
Tertiary (university/polytechnic) 21.5 0.86 0.46, 1.59 0.64 0.29, 1.42
Marital status
Not married 40.0 1.00 1.00
Married 20.9 0.40 0.16, 0.88* 0.29 0.11, 0.77*
Gravidity (number of pregnancies)
Primigravid (first pregnancy) 11.8 1.00 1.00
Multiparous (2/more children) 23.7 2.33 0.78, 7.00 1.17 0.30, 4.63
Grand multiparous (≥5 children) 29.6 3.15 0.92, 10.74 0.85 0.15, 4.69
Maternal risk factors (Yes/No)
Family history of diabetes
No 28.4 1.00 1.00
Yes 17.8 0.55 0.31, 1.00 0.69 0.31, 1.54
Previous history of GDM
No 23.4 1.00 1.00
Yes 18.2 0.73 0.15, 3.47 3.68 0.58, 23.40
Previous baby > 4 kg
No 15.5 1.00 1.00
Yes 50.9 5.65 2.94, 10.86* 6.08 2.46, 15.01*
Previous stillbirth
No 23.4 1.00 1.00
Yes 18.2 0.73 0.15, 3.47 0.51 0.07, 3.70
Previous neonatal death
No 22.9 1.00 1.00
Yes 30.0 1.45 0.36, 5.78 2.92 0.46, 18.72
Maternal BMI (kg/m2)
Underweight / normal) 17.1 1.00 1.00
Overweight 15.0 0.85 0.25, 2.93 0.93 0.21, 4.12
Obese (classes 1–3, ≥30.0) 26.3 1.72 0.67, 4.43 1.11 0.33, 3.71
Antenatal factors
Booking age of gestation (weeks)
1st trimester (0–13) 12.7 1.00 1.00
2nd trimester (14–27) 26.9 2.53 1.18, 5.45* 1.59 0.60, 4.25
3rd trimester (≥28) 31.0 3.09 1.22, 7.85* 0.67 0.18, 2.57
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Although the prevalence of neonatal hypoglycaemia
was higher in this study than in previous studies involv-
ing European (3–4%) [35, 51] and other Pacific Islander
(16.6%) women with GDM [32, 35], the association with
maternal BMI was consistent with reports from Brazil
[42], Spain [42], Australia [43] and New Zealand [29, 34]
among women with GDM. The burden of adult over-
weight, obesity, and associated non-communicable dis-
eases (NCDs) has been widely acknowledged in at least
17 Pacific Island countries, including Fiji, which have
current national NCD plans or strategies in place [52].
The findings of this study suggest the need for a pre-
pregnancy program that incorporates both lifestyle and
dietary interventions in addressing the issue of obesity
among Fijian women with GDM [53].
Another important finding of this study was the sig-
nificant reduction in the odds of all three key outcomes
particularly for neonatal hypoglycaemia and low Apgar
score, among women who delivered at term (38–41
weeks of gestation) compared to those who delivered be-
fore 37 weeks of gestation. Similar association between
pre-term delivery and hypoglycaemia have been reported
not only among women with GDM [54, 55] but also
among those without GDM [56] and the risk increased
with the level of hyperglycaemia [57]. The rate of
preterm delivery in this cohort (17%) was almost double
the rate that was reported for the background popula-
tion (9.9%) in 2012 [34]. In this study, infants who were
delivered at term were less likely to have low Apgar
score compared to infants who were delivered preterm.
This finding may be related to the fact that fewer
women had preterm or caesarean deliveries compared
with those who had delivered at term or by vaginal de-
livery (Table 1). A previous study found that low Apgar
scores at 5 min was more frequent in infants who were
delivered preterm or by caesarean section compared
with infants who were delivered at term or by vaginal
delivery [58].
There were other serious adverse outcomes in this
study such as shoulder dystocia, stillbirths, and NICU
admissions (Fig. 2) which were also worse in this popula-
tion compared to other Pacific Islands women with
GDM [11, 32, 35, 36]. These may reflect the higher bur-
den of the disease [59] as well as the low quality of ob-
stetric care in public hospitals in Fiji. Ensuring that
pregnant women with GDM, particularly those at high
risk of complications, are capable of self-monitoring
their glucose levels by making available home blood glu-
cose meters (which currently is not possible due to lack
of affordability) will help improve pregnancy outcomes
Table 2 Prevalence, unadjusted (OR) and odds ratios (AOR) for neonatal macrosomia among Fijian women with GDM, 2013–2014
(Continued)
Variables Prevalence of macrosomia (%) OR 95% CI AOR 95% CI
Gestational age at GDM diagnosis (weeks)
1st trimester (0–13) 3.9 1.00 1.00
2nd trimester (14–27) 21.6 6.90 0.89, 53.53 3.44 0.34, 34.81
3rd trimester (≥27) 28.8 10.12 1.32, 77.67* 4.30 0.41, 45.30
Gestational age at delivery (weeks)
< 37 9.1 1.00 1.00
37–41 26.1 3.53 1.21, 10.31* 2.72 0.75, 9.86
Maternal post-pregnancy factors
Delivery intervention
Induced labour
No 23.3 1.00 1.00
Yes 23.1 0.99 0.18, 0.50 1.37 0.13, 14.30
Caesarean section
No 24.3 1.00 1.00
Yes 20.5 0.80 0.42, 1.54 1.16 0.55, 3.49
Preeclampsia
No 23.2 1.00 1.00
Yes 22.9 0.98 0.47, 2.08 1.13 0.43, 3.02
*Confidence Interval (CI) that does not include 1.00, significant
BMI body mass index, GDM gestational diabetes mellitus, FIDs Fijians of Indian Descent
§others means part-Europeans, Chinese, and other Pacific Islanders
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Table 3 Prevalence, unadjusted (OR) and odds ratios (AOR) for neonatal hypoglycaemia among Fijian women with GDM, 2013–2014
Variables Prevalence of hypoglycaemia (%) OR 95% CI AOR 95% CI
Maternal sociodemographic factors
Age (years)
18–25 21.7 1.00 1.00
26–35 22.6 1.05 0.48, 2.33 0.82 0.32, 2.14
≥ 36 34.7 1.91 0.77, 4.77 1.31 0.40, 4.35
Race/ethnicity
Others§ 31.8 1.00 1.00
Itaukei Fijians 26.2 0.76 0.29, 2.03 0.97 0.30, 3.13
FIDs 21.7 0.59 0.22, 1.63 0.95 0.26, 3.47
Educational level
Non-tertiary (primary/secondary) 26.9 1.00 1.00
Tertiary (university/polytechnic) 21.5 0.74 0.41, 1.37 0.76 0.37, 1.56
Marital status
Not married 27.6 1.00 1.00
Married 24.4 0.85 0.36, 2.03 0.72 0.26, 1.97
Gravidity (number of pregnancies)
Primigravid (first pregnancy) 11.8 1.00 1.00
Multiparous (2/more children) 27.3 2.81 0.94, 8.40 2.42 0.67, 8.73
Grand multiparous (≥5 children) 25.0 2.50 0.72, 8.70 1.46 0.29, 7.42
Maternal risk factors (yes, no)
Family history of diabetes
No 26.8 1.00 1.00
Yes 22.8 0.81 0.46, 1.43 0.95 0.47, 1.95
Previous history of GDM
No 24.3 1.00 1.00
Yes 36.4 1.78 0.50, 6.30 0.83 0.16, 4.39
Previous baby > 4 kg
No 22.6 1.00 1.00
Yes 32.7 1.66 0.87, 3.20 1.19 0.51, 2.76
Previous stillbirth
No 24.7 1.00 1.00
Yes 27.3 1.14 0.29, 4.45 1.42 0.27, 7.45
Previous neonatal death
No 24.2 1.00 1.00
Yes 40.0 2.09 0.57, 7.66 3.96 0.79, 19.90
Maternal BMI (kg/m2)
Underweight/normal (< 25) 8.8 1.00 1.00
Overweight (25–29.9) 32.5 4.98 1.28, 19.33* 5.49 1.01, 29.96*
Obese (classes 1–3, ≥30.0) 27.5 3.92 1.14, 13.48* 4.34 0.87, 21.65
Antenatal factors
Booking age of gestation (weeks)
1st trimester (0–13) 24.1 1.00 1.00
2nd trimester (14–27) 25.6 1.08 0.57, 2.07 1.72 0.68, 4.34
3rd trimester (≥28) 23.8 0.99 0.41, 2.37 1.09 0.30, 3.95
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in GDM. Additionally, the high rate of low Apgar scores
found in this study indicates the need for regular audit
of the diabetes clinic to identify areas of improvement in
the quality of care.
Pacific Islands women are known to book late in gesta-
tion [9] and this was reflected in our study where more
than two-thirds of the women had late booking (booked
after 13 weeks of gestation). In a recent randomised RCT,
early booking in gestation identified pregnant women who
can benefit from early treatment for GDM, to reduce preg-
nancy complications [60]. In the TOBOGM study, 89% of
untreated women had GDM early in gestation (at both 18
weeks and 24–28weeks gestation), making the case for
early screening in pregnancy [60], however, the decision as
to whether to treat or not early in gestation remains contro-
versial. The present study found that early booking in gesta-
tion was associated with some reduction in the odds of
macrosomia and significant reduction in the odds of low
Apgar score by up to 80% (Table 4). Public health officers
need to step up effective targeted strategies to promote
early booking in gestation preferably in the first trimester of
pregnancy, among women with and without GDM.
The limitations of this study were that: 1), the findings
cannot be generalized to the entire population of pregnant
women with GDM in Fiji because we only considered
women with GDM from a single hospital registry in urban
Fiji; 2), the study reported outcomes of mothers with
GDM without a control group for direct comparison. Fu-
ture studies should compare the sociodemographic factors
associated with adverse outcomes between women with
and without GDM; 3), the study did not adequately test
the effect of pre-pregnancy BMI and data for gestational
weight gain was not captured. However, with the high
prevalence of overweight and obesity in this study, it is
critical to understand the effect of maternal body mass on
neonatal outcomes; 4), although the use of glucose chal-
lenge tests for screening those with no risk factors is an ac-
ceptable approach [61], the test potentially misses those
with fasting hyperglycaemia, thus OGTT was performed in
this study; and 5), the study used a cut-off point of < 1.6 for
Table 3 Prevalence, unadjusted (OR) and odds ratios (AOR) for neonatal hypoglycaemia among Fijian women with GDM, 2013–2014
(Continued)
Variables Prevalence of hypoglycaemia (%) OR 95% CI AOR 95% CI
Age of gestation at GDM diagnosis (weeks)
1st trimester (0–13) 38.5 1.00 1.00
2nd trimester (14–27) 21.6 0.44 0.18, 1.10 0.40 0.10, 1.52
3rd trimester (≥27) 24.8 0.53 0.22, 1.29 0.53 0.13, 2.17
Age of gestation at delivery (weeks)
< 37 39.5 1.00 1.00
37–41 21.8 0.43 0.21, 0.85* 0.38 0.17, 0.89*
Maternal post-pregnancy factors
Delivery intervention
Induced labour
No 23.3 1.00 1.00
Yes 25.6 1.14 0.62, 2.09 0.52 0.06, 4.20
Caesarean section
No 21.0 1.00 1.00
Yes 33.3 1.88 1.04, 3.40 2.86 0.15, 56.32
Preeclampsia
No 22.8 1.00 1.00
Yes 33.3 1.69 0.86, 3.35 1.32 0.59, 3.01
Polyhydramnios
No 24.6 1.00 1.00
Yes 50.0 3.06 0.18, 49.72 2.32 0.11, 48.31
Endometritis
No 24.7 1.00 –
Yes 50.0 3.05 0.19, 49.5 – –
*Confidence Interval (CI) that does not include 1.00, significant
BMI body mass index, GDM gestational diabetes mellitus, FIDs Fijians of Indian Descent
§others means part-Europeans, Chinese, and other Pacific Islanders
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Table 4 Prevalence, unadjusted (OR) and odds ratios (AOR) for lower Apgar scores among Fijian women with GDM, 2013–2014
Variables Prevalence of low Apgar score (%) OR 95% CI AOR 95% CI
Maternal sociodemographic factors
Age (years)
18–25 15.2 1.00 1.00
26–35 13.9 0.90 0.36, 2.27 0.97 0.26, 3.59
≥ 36 8.2 0.50 0.14, 1.82 0.18 0.02, 1.44
Race/ethnicity
Othersa 9.1 1.00 1.00
Itaukei Fijians 11.2 1.26 0.27, 5.98 1.32 0.20, 8.61
FIDs 16.0 1.91 0.41, 8.94 1.60 0.21, 11.92
Educational level
Non-tertiary (primary/secondary) 16.0 1.00 1.00
Tertiary (university/polytechnic) 8.7 0.50 0.22, 1.16 0.54 0.18, 1.62
Marital status
Not married 10.3 1.00 1.00
Married 13.4 1.34 0.38, 4.70 1.66 0.35, 7.85
Gravidity (number of pregnancies)
Primigravid (first pregnancy) 11.8 1.00 1.00
Multiparous (2/more children) 14.3 1.25 0.41, 3.85 2.77 0.58, 13.29
Grand multiparous (≥5 children) 9.1 0.75 0.17, 3.24 1.77 0.19, 16.60
Maternal risk factors (yes, no)
Family history of diabetes
No 13.4 1.00 1.00
Yes 12.7 0.94 0.45, 1.96 1.40 0.52, 3.76
Previous baby > 4 kg
No 13.6 1.00 1.00
Yes 10.9 0.78 0.30, 1.99 1.64 0.45, 5.95
Previous neonatal death
No 13.2 1.00 1.00
Yes 10.0 0.73 0.09, 5.98 1.49 0.12, 18.50
Maternal BMI (kg/m2)
Underweight/normal (< 25) 14.7 1.00 1.00
Overweight (25–29.9) 22.5 1.68 0.50, 5.62 1.58 0.37, 6.70
Obese (classes 1–3, ≥30.0) 10.7 0.69 0.24, 2.03 0.28 0.07, 1.16
Antenatal factors
Booking age of gestation (weeks)
1st trimester (0–13) 11.4 1.00 1.00
2nd trimester (14–27) 12.9 1.15 0.49, 2.72 1.46 0.44, 4.85
3rd trimester (≥28) 16.7 1.56 0.54, 4.53 7.87 1.11, 55.75*
Age of gestation at GDM diagnosis (weeks)
1st trimester (0–13) 11.5 1.00 1.00
2nd trimester (14–27) 15.5 1.40 0.38, 5.19 1.53 0.24, 10.01
3rd trimester (≥27) 11.1 0.96 0.25, 3.64 0.53 0.06, 4.56
Age of gestation at delivery (weeks)
< 37 27.9 1.00 1.00
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neonatal hypoglycaemia that should be considered when
interpreting the results. Despite these limitations, the high
prevalence of key neonatal outcomes of macrosomia and
hypoglycaemia, may not have been different in this study,
since previous studies have reported similar worse out-
comes among women with GDM who were under strict
glycaemic control [32, 35]. Similar to some studies [11, 62],
we used the modified IADPSG criteria since the 1 h glucose
was not available, which may have underestimated the odd
ratios as more women with GDM could have been diag-
nosed using a 1 h blood glucose test compared to the 2-h
glucose test (36% versus 13%) [63]. To be able to assess the
impact of the IADPSG criteria in our setting, future studies
should compare the maternal and fetal outcomes of women
with GDM who were diagnosed using a 1 h blood glucose
test and those diagnosed using the 2-h glucose test, to pro-
vide an opportunity for assessment of the cost effectiveness
of both approaches.
This study has some strengths including inclusion of
other clinical variables in the multivariable analysis, pro-
viding baseline information with which the ongoing uni-
versal testing can be assessed and allow endorsement of
awareness campaigns to provide more knowledge on the
adverse effects of GDM on neonates. The maternal
socio-demographic characteristics as well as factors
identified in this study can be used to develop future in-
terventions to optimize maternal and infant health out-
comes among Fijian women with GDM. The findings
alert the health care providers on the high rate of
macrosomia, hypoglycaemia and low Apgar Score in an
urban Fiji population, and can alert Fijian women of
their increased risk of adverse neonatal outcomes. While
there are no published hyperglycaemia in pregnancy data
from Fiji, this study showed worse birth outcomes com-
pared to our earlier work (1994–1998) among Polyne-
sians (including Fijians) and Europeans in South
Auckland, New Zealand [35] which may be attributed to
the anthropomorphic effects of the Fijian population.
Given that 80% of births in the Central Eastern division
occur in CWM hospital, it is likely that these findings
may represent the Central Eastern division population.
Conclusions
This study has shown that offsprings of Fijian women with
GDM have serious negative outcomes specifically macroso-
mia, hypoglycaemia and Apgar score. The risk increases
among overweight/obese women, women with a previous
baby weighing > 4 kg, had delivered pre-term babies, had
pre-eclampsia and those who booked later than 13weeks in
gestation. These factors should be taken into account when
preventive intervention strategies are developed to improve
outcomes and the target risk group is established. The high
incidence of complications reported in this paper is clear evi-
dence of the burden of GDM. Public enlightenment cam-
paigns promoting booking in the first trimester among
women with GDM and effective lifestyle interventions to
prevent excessive weight gain in pregnancy are needed to im-
prove the outcomes of pregnancies with GDM in the short
term, and to reduce the long-term risk of type 2 diabetes for
both mothers and their children.
Table 4 Prevalence, unadjusted (OR) and odds ratios (AOR) for lower Apgar scores among Fijian women with GDM, 2013–2014
(Continued)
Variables Prevalence of low Apgar score (%) OR 95% CI AOR 95% CI
37–41 10.0 0.29 0.13, 0.64* 0.14 0.04, 0.46*
Maternal post-pregnancy factors
Delivery intervention
Induced labour
No 10.6 1.00 1.00
Yes 14.3 1.41 0.62, 3.18 0.16 0.01, 2.52
Caesarean section
No 15.4 1.00 1.00
Yes 7.7 0.46 0.18, 1.16 2.86 0.16, 56.32
Preeclampsia
No 11.2 1.00 1.00
Yes 20.8 2.08 0.92, 4.73 5.57 1.73, 18.00*
Polyhydramnios
No 12.8 1.00 1.00
Yes 50.0 6.84 0.42, 112.15 10.51 0.34, 326.38
*Confidence Interval (CI) that does not include 1.00, significant
BMI body mass index, GDM gestational diabetes mellitus, FIDs Fijians of Indian Descent
§others means part-Europeans, Chinese, and other Pacific Islanders
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